Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data

Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.

Related Keywords

Thomas Krivak ,Thomas Herzog ,Caris ,Ovarian Cancer ,Homologous Recombination Deficiency ,Hrd Testing ,Oc Treatment ,Hoc Outcomes ,Hrr Pathway ,Homologous Recombination Repair ,